MedTrace Logo

Efficacy and Safety of Irbesartan and Atorvastatin in Hypertension and Hyperlipidemia

NCT01442987 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 230

Last updated 2013-08-13

No results posted yet for this study

Summary

The purpose of this study is to evaluate efficacy and safety of coadministered Irbesartan and Atorvastatin in patients with hypertension and hyperlipidemia.

Conditions

Interventions

DRUG

Irbesartan/Atorvastatin A

once daily, P.O. 8week

DRUG

Irbesartan

once daily, P.O. 8week

DRUG

Atorvastatin A

once daily, P.O. 8week

DRUG

Placebo

once daily, P.O. 8week

DRUG

Irbesartan/Atorvastatin B

once daily, P.O. 8week

DRUG

Atorvastatin B

once daily, P.O. 8week

Sponsors & Collaborators

  • Hanmi Pharmaceutical Company Limited

    lead INDUSTRY

Principal Investigators

  • Byeong Hee Oh, M.D · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2013-04-30
Completion
2013-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01442987 on ClinicalTrials.gov